JNJ News 100.76 05/30/2014 05:08:11 Johnson & Johnson (JNJ)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Johnson & Johnson (JNJ) 100.76 $JNJ

Global Elephantiasis (Lymphatic Filariasis) Therapeutics Pipeline Report 2014
M2 - 1 hr 14 mins ago
Research and Markets (http://www.researchandmarkets.com/research/bt9h9z/elephantiasis) has announced the addition of the "Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H1 2014" report to their offering. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. This report provides comprehensive information on the therapeutic development for Elephantiasis (Lymphatic Filariasis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Elephantiasis (Lymphatic Filariasis) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development - Johnson & Johnson - Eisai Co., Ltd. - Anacor Pharmaceuticals, Inc. Scope - The report provides a snapshot of the global therapeutic landscape of Elephantiasis (Lymphatic Filariasis) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Elephantiasis (Lymphatic Filariasis) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Elephantiasis (Lymphatic Filariasis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Elephantiasis (Lymphatic Filariasis) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products For more information visit http://www.researchandmarkets.com/research/bt...phantiasis

Treatment Resistant Depression - Therapeutics Pipeline Review 2014
M2 - 1 hr 14 mins ago
Research and Markets (http://www.researchandmarkets.com/research/l2gkp7/treatment) has announced the addition of the "Treatment Resistant Depression - Pipeline Review, H1 2014" report to their offering. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. This report provides comprehensive information on the therapeutic development for Treatment Resistant Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Treatment Resistant Depression and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Taisho Pharmaceutical Co., Ltd. - Avanir Pharmaceuticals, Inc. - Naurex, Inc. - MarcoPolo Pharmaceuticals SA - Edgemont Pharmaceuticals, LLC Scope - The report provides a snapshot of the global therapeutic landscape of Treatment Resistant Depression - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Treatment Resistant Depression and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Treatment Resistant Depression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Treatment Resistant Depression pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products For more information visit http://www.researchandmarkets.com/research/l2gkp7/treatment

China fines eye-care companies on pricing charges
AP - Thu May 29, 11:34PM CDT
BEIJING (AP) — China has fined Johnson & Johnson, Nikon Corp. and five other makers of eyeglasses and contact lenses on price-fixing charges in its latest effort to use anti-monopoly law to control consumer prices.

Midday Glance: Pharmaceuticals companies
AP - Thu May 29, 12:25PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:

Midday Glance: Medical Devices companies
AP - Thu May 29, 12:25PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:

Early Glance: Pharmaceuticals companies
AP - Thu May 29, 9:51AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:

Early Glance: Medical Devices companies
AP - Thu May 29, 9:51AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:

Veracyte, Foundation Medicine and Panacea Global Paving Way in Faster, More Accurate Cancer Diagnostics
ACCESSWIRE - Thu May 29, 8:53AM CDT
Whitefish, MT / May 29, 2014 / Most of the science behind disease is only truly understandable by scientists, researchers, and physicians rather than the general population. What everyone does understand is that, in virtually every scenario, early detection is a key to treatment or even survivorship. The life sciences IPO boom that started in 2013 has created some additional wind under the sails of few diagnostics companies, including Veracyte Inc. (NASDAQ: VCYT) and Foundation Medicine Inc. (NASDAQ: FMI), and it should have investors taking a closer look at upstart Panacea Global, Inc. (OTCQB: PANG) and its new cancer-detecting technology.

Aduro Announces License Agreement with Johnson & Johnson Innovation for Novel Immunotherapies for Prostate Cancer
Business Wire - Thu May 29, 7:01AM CDT
Aduro BioTech, Inc., a clinical-stage biotechnology company, today announced that it has entered into an agreement granting Janssen Biotech, Inc. (Janssen) an exclusive, worldwide license to certain product candidates specifically engineered for the treatment of prostate cancer based on its novel LADD immunotherapy platform. Under the agreement, facilitated by the Johnson & Johnson Innovation center in California, Aduro is eligible to receive up to $365 million in upfront license fees and milestone payments upon achievement of defined development, regulatory and commercialization milestones, if multiple programs advance to commercialization, as well as tiered royalties on worldwide net sales.

Insomnia - Pipeline Review, H1 2014: Includes 16 Company Profiles
M2 - Thu May 29, 6:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lslnv2/insomnia) has announced the addition of the "Insomnia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Insomnia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Insomnia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report provides a snapshot of the global therapeutic landscape of Insomnia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Insomnia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Insomnia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Mentioned: - Abeille Pharmaceuticals - Actelion - Angelini - Eisai - Evotec - Grupo Ferrer Internacional - Heptares Therapeutics - Intec Pharma - IntelGenx - Intra-Cellular Therapies - Johnson & Johnson - Merck & Co - Mitsubishi Tanabe Pharma - Neurim Pharmaceuticals - Novartis - Somnus Therapeutics For more information visit http://www.researchandmarkets.com/research/lslnv2/insomnia

United States In-Vitro Diagnostic Substance Manufacturing Industry and its International Trade 2014 Report
M2 - Thu May 29, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4g2jmr/invitro) has announced the addition of Supplier Relations US, LLC's new report "United States In-Vitro Diagnostic Substance Manufacturing Industry and its International Trade 2014 Report" to their offering. This U.S. industry comprises establishments primarily engaged in manufacturing in-vitro (i.e., not taken internally) diagnostic substances, such as chemical, biological, or radioactive substances. The substances are used for diagnostic tests that are performed in test tubes, petri dishes, machines, and other diagnostic test-type devices. This latest In-Vitro Diagnostic Substance Manufacturing Industry report provides the most updated market research on the industry. Its scope contains analysis on the industry's key financial data, competitive landscape, shipment and inventory data, upstream and downstream industries, and trade data. This 2014 report's 174 pages and over 150 charts and tables cover the domestic market, global market and overseas growth opportunities. Find the latest data on shipments, inventory, international trade, and essential industry price indices available through December 2013. In this report, you will find industry data on the following major categories: - Executive Summary - Industry Income Statement - Industry Balance Sheet - Capital Expenditure - Industry Cost Analysis - Industry Pricing Analysis - Industry Foreign Trade - Industry Structure - Competitive Landscape Companies Mentioned - Abaxis Inc. - Affymetrix, Inc. - Alere - Amag Pharmaceuticals Inc. - ARCA biopharma - Bracco Diagnostic Inc. - Celsis In Vitro Technologies - EXACT Sciences Corporation - General Electric Company - Hologic, Inc. - IDEXX Laboratories, Inc. - Johnson & Johnson - Monogram Biosciences, Inc. - Myriad Genetics, Inc. - OraSure Technologies, Inc. - Peregrine Pharmaceuticals, Inc. - Quidel Corporation - Radient Pharmaceuticals Corporation For more information visit http://www.researchandmarkets.com/research/4g2jmr/invitro

United States Surgical and Medical Instrument Manufacturing Industry and its International Trade Report 2014 Edition
M2 - Thu May 29, 5:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gx58k6/surgical_and) has announced the addition of Supplier Relations US, LLC's new report "Surgical and Medical Instrument Manufacturing Industry in the U.S. and its International Trade [2014 Edition]" to their offering. This U.S. industry comprises establishments primarily engaged in manufacturing medical, surgical, ophthalmic, and veterinary instruments and apparatus (except electrotherapeutic, electromedical and irradiation apparatus). Examples of products made by these establishments are syringes, hypodermic needles, anesthesia apparatus, blood transfusion equipment, catheters, surgical clamps, and medical thermometers. The Surgical and Medical Instrument Manufacturing Industry report contains the most recent data and analysis on the industry's key financial data, cost and pricing, competitive landscape, industry structure. Also updated are the latest trade, shipment, and inventory data available through December 2013. This update provides the data necessary to make informed forecasts and business planning after the recent seasonal changes in output. This 174-page report includes the most recent information on the domestic market, global market and overseas growth opportunities. This report provides the most current data available, such as shipments, inventory and trade data available through December 2013, and sophisticated forecasts up to 2017 accounting for the affects of the recent economic recession. Industry analysts consider this report the most comprehensive and consistently updated guide to the industry. In this report, you will find industry data on the following major categories: - Executive Summary - Industry Income Statement - Industry Balance Sheet - Capital Expenditure - Industry Cost Analysis - Industry Pricing Analysis - Industry Foreign Trade - Industry Structure - Competitive Landscape Companies Mentioned - Abbott Laboratories - Allergan, Inc. - Bausch & Lomb Incorporated - Baxter International Inc. - Becton, Dickinson & Company - Bio-Rad Laboratories, Inc. - Boston Scientific Corporation - Bristol-Myers Squibb Company - C.R. Bard, Inc. - Cooper Companies Inc. - Covidien - Edwards Lifesciences Corporation - General Electric Company - Hill-Rom - Hologic, Inc. - Hospira, Inc. - Johnson & Johnson - Pall Corporation - STERIS Corporation - Stryker Corporation - Teleflex Incorporated For more information visit http://www.researchandmarkets.com/research/gx...rgical_and

United States Surgical Appliance and Supplies Manufacturing Industry and its International Trade [2014 Edition]
M2 - Thu May 29, 4:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bpjwbd/surgical) has announced the addition of Supplier Relations US, LLC's new report "Surgical Appliance and Supplies Manufacturing Industry in the U.S. and its International Trade [2014 Edition]" to their offering. This U.S. industry comprises establishments primarily engaged in manufacturing surgical appliances and supplies. Examples of products made by these establishments are orthopedic devices, prosthetic appliances, surgical dressings, crutches, surgical sutures, and personal industrial safety devices (except protective eyewear). This 2014 publication of Surgical Appliance and Supplies Manufacturing Industry report is the comprehensive market research guide for the industry. It contains the latest information on the industry's key financial data, competitive landscape, cost and pricing, and trends during the current environment, including the output and shipment changes over the past months. In this report, you will find industry data on the following major categories: - Executive Summary - Industry Income Statement - Industry Balance Sheet - Capital Expenditure - Industry Cost Analysis - Industry Pricing Analysis - Industry Foreign Trade - Industry Structure - Competitive Landscape Companies Mentioned - Baxter International Inc. - Becton, Dickinson & Company - Boston Scientific Corporation - Cardinal Health, Inc. - Cooper Companies Inc. - Covidien - Edwards Lifesciences Corporation - Hill-Rom - Intuitive Surgical, Inc. - Invacare Corporation - Johnson & Johnson - Kimberly-Clark Corporation - Kinetic Concepts, Inc. - Medtronic, Inc. - Mine Safety Appliances Company - Pall Corporation - Royal Philips Electronics - St. Jude Medical, Inc. - STERIS Corporation - Stryker Corporation - Synthes North America - Teleflex Incorporated - West Pharmaceutical Services, Inc. - Wright Medical Group, Inc. - Zimmer Holdings, Inc. For more information visit http://www.researchandmarkets.com/research/bpjwbd/surgical

Major Depressive Disorder - Pipeline Review, H1 2014: Includes 30 Company Profiles
M2 - Thu May 29, 3:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8lbldl/major_depressive) has announced the addition of the "Major Depressive Disorder - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Major Depressive Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Major Depressive Disorder and special features on late-stage and discontinued projects. This report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Alkermes - Angelini Group - Aniona - AstraZeneca - BRAINco Biopharma - Bionure - BrainCells Inc. - Cerecor Inc. - Dainippon Sumitomo Pharma - Dart NeuroScience - Edgemont Pharmaceuticals - Eli Lilly and Company - Euthymics Bioscience - F. Hoffmann-La Roche - Fabre-Kramer Pharmaceuticals - H. Lundbeck - Intas Pharmaceuticals - Johnson & Johnson - Luye Pharma Group - M's Science Corporation - Methylation Sciences - Naurex - NeurOp Corporation - Neuralstem - Neurocrine Biosciences - OPKO Health - Otsuka Holdings - PharmaNeuroBoost - Reviva Pharmaceuticals - Richter Gedeon - Sunovion Pharmaceuticals - Suven Life Sciences - Taisho Pharmaceutical Co., Ltd. - e-Therapeutics plc - nLife Therapeutics, S.L. For more information visit http://www.researchandmarkets.com/research/8l...depressive

Final Glance: Medical Devices companies
AP - Wed May 28, 5:02PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:

Final Glance: Pharmaceuticals companies
AP - Wed May 28, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:

AbbVie Up on HCV Filing in Canada - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 28, 2:04PM CDT
AbbVie Inc. (ABBV) filed new drug submission (NDS) to Health Canada for its investigational hepatitis C virus (HCV) infection therapy.

EU Nod for Eli Lilly/Boehringer's Jardiance (revised) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 28, 1:26PM CDT
Eli Lilly and Company (LLY) and partner Boehringer Ingelheim announced that the European Commission (EC) has approved their sodium glucose co-transporter-2 (SGLT2) inhibitor, Jardiance
Scroll down for more posts ▼

Top 10 Most Recent News Articles

S&P Global's December 8 Talk Puts Guidance in Focus

Updated Category News Views 54

A 35-minute fireside chat can be a whole lot of nothing, or it can leave a useful breadcrumb trail for shareholders willing to listen closely. S&P Global has put December 8, 2026 on the calendar, when Chief Executive Officer Martina Cheung is scheduled to appear at Goldman Sachs' 2026 Financial Services Conference in New York. Her slot runs from 5:00 p.m. to 5:35 p.m....

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 52

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading
Nevada’s Space Academy Bid Has Assets, Not a Win Yet

Updated Category News Views 29

Desert acreage and a moon-landing backstory make for a handsome pitch, but Nevada is still standing at the starting line. The state has submitted its official response to NASA’s Request for Information for a proposed United States Space Academy, and the new promotional video is meant to show why the Silver State belongs in the conversation. Fair enough. There is real...

Continue Reading
Mars Sets $2 Billion Debt Tender With Kellanova Notes

Updated Category News Views 124

A two-billion-dollar vacuum cleaner just switched on inside Mars’s debt stack, and the timing is anything but casual. On November 20, Mars fixed the pricing for cash tender offers spanning selected Mars and Kellanova senior notes, with holders facing a 5:00 p.m. New York deadline that same day. This is the kind of filing that looks like bond-market plumbing until you...

Continue Reading
TEN Holdings Raises $1.0 Million as Dilution Looms

Updated Category News Views 66

A Small Raise With a Loud Message Nothing says “we need room to breathe” quite like selling 1,492,500 new shares for $0.67 apiece. TEN Holdings closed a roughly $1.0 million gross equity offering on November 20, 2026, and investors in NASDAQ:XHLD ought to look at this for what it is: a modest cash infusion that comes with immediate dilution. The company gets capital;...

Continue Reading
Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 149

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
Saturn and Tileward Put GPU Memory Back to Work Now

Updated Category News Views 49

GPU memory is the tollbooth nobody notices until the whole AI highway backs up. Saturn Cloud’s new partnership with Tileward goes straight at that constraint: use compressed open-model weights, free memory on hardware already installed, and turn that reclaimed capacity into more tokens that an operator can actually sell. It is not glamorous. It may be one of the more...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 78

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 73

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Tampa General's Food Bet Earns a 2026 Innovation Award

Updated Category News Views 41

Hospital meals have long been the punchline nobody bothered to fix, which is why Tampa General Hospital's latest recognition deserves a closer look. The not-for-profit academic health system was named the 2026 Inno Pick by the Tampa Bay Business Journal for its Food as Medicine initiative, its fifth straight year landing among the publication's Inno Award honorees. Awards...

Continue Reading

Top 5 Most Recently Viewed Articles

Ivalua Celebrates Winning Multiple Best Company Awards

Updated Category News Views 104

Ivalua Celebrates Its Recognition with Multiple Best Company Awards Ivalua, a leader in spend management solutions, is excited to share its recent achievements at the Comparably Awards. The company received accolades for Happiest Employees, Best Company Perks & Benefits, and Best Company Work-Life Balance. This recognition underscores Ivalua's commitment to creating an...

Continue Reading
Global Peace Index Reveals Increasing Conflict Trends

Updated Category News Views 371

The 2025 Global Peace Index: A Rising Tide of Conflict The recently released 2025 Global Peace Index (GPI) by the Institute for Economics & Peace (IEP) highlights a troubling trend of declining global peacefulness. The report indicates that we are witnessing a significant change in the global landscape, pointing to a stark reality where conditions leading to conflict are...

Continue Reading
Innovative Device Revolutionizes Painting Techniques and Efficiency

Updated Category News Views 227

Transformative Invention for Painters In the world of painting, efficiency and effectiveness are paramount. Inventors continually seek ways to improve the tools that workers use. One new device, the LOCK & ROLL, aims to enhance the painting experience significantly. Introduction to the LOCK & ROLL This innovative invention is designed to securely anchor paint rollers atop...

Continue Reading
Norfolk Southern's Leadership Crisis: Alan Shaw's Upcoming Exit

Updated Category News Views 130

Norfolk Southern at a Crossroads as Alan Shaw Faces Scrutiny Norfolk Southern Corporation is navigating a tense moment. Chief Executive Alan Shaw is under investigation for alleged ethical violations, including a purported relationship with a company employee. The review has raised questions about leadership, culture, and what accountability should look like at one of the...

Continue Reading
West USA Realty Partners with Zillow to Enhance Listings

Updated Category News Views 235

West USA Realty Embraces Transparency with Zillow West USA Realty, a leading name in the real estate industry, is taking a bold step by aligning with Zillow's standards for consumer access to property listings. This partnership reflects a mutual commitment to transparency and aims to enhance the experience for home buyers and sellers alike. Commitment to Consumers As the...

Continue Reading